OTCMKTS:OTLC Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis $0.01 +0.00 (+1.54%) As of 11/13/2026 03:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Oncotelic Therapeutics Stock (OTCMKTS:OTLC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oncotelic Therapeutics alerts:Sign Up Key Stats Today's Range$0.0113▼$0.013950-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.10Volume479,008 shsAverage Volume460,984 shsMarket Capitalization$6.03 millionP/E Ratio0.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research includes therapies intended to affect biological pathways involved in tumor growth and the body’s immune response. The company’s lead candidate, OT-101, is an antisense therapy designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has pursued its development for cancers including glioblastoma and pancreatic cancer; it remains an investigational drug, not an approved treatment. The company was previously known as Mateon Corporation and adopted the Oncotelic Therapeutics name in 2019. Its leadership includes founder and Chief Executive Officer Dr. Vuong Trieu.AI Generated. May Contain Errors. Read More Oncotelic Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreOTLC MarketRank™: 2.278597785975 of 5 starsOncotelic Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oncotelic Therapeutics. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncotelic Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncotelic Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.15.Price to Book Value per Share RatioOncotelic Therapeutics has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Oncotelic Therapeutics has been sold short.Short Interest Ratio / Days to CoverOncotelic Therapeutics has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncotelic Therapeutics has recently decreased by 56.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncotelic Therapeutics does not currently pay a dividend.Dividend GrowthOncotelic Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentOncotelic Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oncotelic Therapeutics this week, compared to 1 article on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOncotelic Therapeutics has minimal institutional ownership at this time.Read more about Oncotelic Therapeutics' insider trading history. Receive OTLC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OTLC Stock News HeadlinesOncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer SignatureOctober 26, 2026 | finance.yahoo.comOncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled DiscoveryOctober 20, 2026 | globenewswire.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 15 at 1:00 AM | Traders Agency (Ad)PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026October 5, 2026 | globenewswire.comOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thAugust 3, 2026 | financialpost.comFOncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6thAugust 3, 2026 | globenewswire.comOncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)July 22, 2026 | globenewswire.comOTLC Share News TodayJuly 14, 2026 | uk.investing.comSee More Headlines OTLC Stock Analysis - Frequently Asked Questions How have OTLC shares performed this year? Oncotelic Therapeutics' stock was trading at $0.0775 at the start of the year. Since then, OTLC shares have decreased by 83.0% and is now trading at $0.0132. How were Oncotelic Therapeutics' earnings last quarter? Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) released its quarterly earnings data on Wednesday, April, 15th. The company reported $0.59 EPS for the quarter. How do I buy shares of Oncotelic Therapeutics? Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:OTLC CIK908259 Webwww.oncotelic.com Phone(650) 635-7000Fax650-635-7001Employees41Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.59 Trailing P/E Ratio0.02 Forward P/E RatioN/A P/E GrowthN/ANet Income$249.28 million Net MarginsN/A Pretax Margin143,532.39% Return on Equity123.75% Return on Assets81.36% Debt Debt-to-Equity Ratio0.01 Current Ratio0.08 Quick Ratio0.08 Sales & Book Value Annual Sales$70 thousand Price / Sales86.08 Cash Flow$0.66 per share Price / Cash Flow0.02 Book Value$0.59 per share Price / Book0.02Miscellaneous Outstanding Shares456,490,000Free Float277,456,000Market Cap$6.03 million OptionableNot Optionable Beta-0.10 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (OTCMKTS:OTLC) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncotelic Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.